Lauri Tuure

List of Publications by Year in Descending Order

11 papers	204 citations	6 h-index	13 g-index
13 ext. papers	252 ext. citations	5.3 avg, IF	2.84 L-index

#	Paper	IF	Citations
11	Regulation of gene expression by MF63, a selective inhibitor of microsomal PGE synthase 1 (mPGES1) in human osteoarthritic chondrocytes. *British Journal of Pharmacology*, **2020**, 177, 4134-4146	8.6	4
10	Transient Receptor Potential Ankyrin 1 (TRPA1) Is Involved in Upregulating Interleukin-6 Expression in Osteoarthritic Chondrocyte Models. *International Journal of Molecular Sciences*, **2020**, 22,	6.3	3
9	Downregulation of microsomal prostaglandin E synthase-1 (mPGES-1) expression in chondrocytes is regulated by MAP kinase phosphatase-1 (MKP-1). *International Immunopharmacology*, **2019**, 71, 139-143	5.8	6
8	Activity of rheumatoid arthritis correlates with oral inflammatory burden. *Rheumatology International*, **2018**, 38, 1661-1669	3.6	5
7	PDE4 inhibitor rolipram inhibits the expression of microsomal prostaglandin E synthase-1 by a mechanism dependent on MAP kinase phosphatase-1. *Pharmacology Research and Perspectives*, **2017**, 5, e00363	3.1	2
6	Microsomal Prostaglandin E Synthase-1 Expression in Inflammatory Conditions Is Downregulated by Dexamethasone: Seminal Role of the Regulatory Phosphatase MKP-1. *Frontiers in Pharmacology*, **2017**, 8, 646	5.6	5
5	Anti-Inflammatory Effects of 2-Receptor Agonists Salbutamol and Terbutaline Are Mediated by MKP-1. *PLoS ONE*, **2016**, 11, e0148144	3.7	22
4	Mitogen-activated protein kinase phosphatase 1 as an inflammatory factor and drug target. *Basic and Clinical Pharmacology and Toxicology*, **2014**, 114, 24-36	3.1	46
3	Attenuation of TNF production and experimentally induced inflammation by PDE4 inhibitor rolipram is mediated by MAPK phosphatase-1. *British Journal of Pharmacology*, **2013**, 169, 1525-36	8.6	35
2	Attenuation of the acute inflammatory response by dual specificity phosphatase 1 by inhibition of p38 MAP kinase. *Molecular Immunology*, **2011**, 48, 2059-68	4.3	24
1	Aurothiomalate inhibits cyclooxygenase 2, matrix metalloproteinase 3, and interleukin-6 expression in chondrocytes by increasing MAPK phosphatase 1 expression and decreasing p38 phosphorylation: MAPK phosphatase 1 as a novel target for antirheumatic drugs. *Arthritis and Rheumatism*, **2010**, 62, 1650-9		52